Monthly Archives: June 2021

Hot Biotech Stocks To Buy For 2021

Utility stocks were among the worst-performing sectors of the market earlier this year, but theyre making a roaring comeback.

The utilities-tracking XLU ETF has risen in 13 of the last 14 trading sessions, jumping 10 percent in one month alone. Gina Sanchez, CEO of Chantico Global, told CNBCs Trading Nation on Friday that the run is likely to continue as investors retreat into more stable sectors. Here are her reasons why.

Utilities had taken a backseat to more growth-oriented stocks like technology amid broad economic expansion and the prospect of higher interest rates that could theoretically depress utilities prices. Now, as the market is turning more defensive and a U.S.-China trade tiff has come into focus, utilities look more attractive.

Utilities typically pay substantial dividend yields; the XLU carries a yield of 3.3 percent, and some names within the group pay out even heftier dividends relative to the market.

Hot Biotech Stocks To Buy For 2021: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler — five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies that are innovating treatments and drugs that are making the world healthier. Learn more about Amgen (NASDAQ:AMGN), bluebird bio (NASDAQ:BLUE), Editas Medicine (NASDAQ:EDIT), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) and why you should add these exciting and inspiring stocks to your watch list.

  • [By ]

    Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.

Hot Biotech Stocks To Buy For 2021: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Hot Biotech Stocks To Buy For 2021: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Just last Thursday, March 21, Biogen (Nasdaq: BIIB) and its partner, Japanese biopharmaceutical company Eisai (OTC: ESALY), said that their experimental Alzheimer’s therapy, which at that time was at the second stage of clinical trials, was a bust. BIIB dropped 29.2% on the day, and ESALY by 35% on the same day.

  • [By Chris Hill]

    In this episode ofMotley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS)finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health(NYSE:CVS) diversifies into CBD lotion. Levi Strauss(NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE)sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s(NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc.(NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

  • [By Money Morning News Team]

    Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

Hot Biotech Stocks To Buy For 2021: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Undervalued Stocks To Own Right Now

How Trump’s Tax Act Could Affect Annuity Issuers

5 Big Questions About Life Insurance for 2018

How to Lean Against the Biases in 2018

Trinity Place Holdings Inc. has closed on $189.5 million in construction financing for its new 300,000-square-foot mixed-use development at 77 Greenwich St. in Lower Manhattan, in New York City.

The project calls for the construction of an approximately 500-foot tall tower building that will contain 90 luxury condominium units, the adaptive reuse of the landmarked Robert and Anne Dickey House, 7,500 square feet of street level retail space, and construction of a new wheelchair-accessible subway entrance on Trinity Place.

The construction loan has a four-year term with one extension option. The loan, in addition to equity already funded by Trinity Place and future contributions by the New York City School Construction Authority, will cover anticipated future costs of the project. The project hard costs are 93% “bought out” and are managed under a gross maximum price construction contract, Trinity Place reports. In its press announcement, Trinity did not provide any further financial details of the transaction, including the identity of the lender.

Top 5 Undervalued Stocks To Own Right Now: Ecolab Inc.(ECL)

Ecolab was incorporated as a Delaware corporation in 1924. Our fiscal year is the calendar year ending December 31.

In 2015, we took several actions to continue to invest in and build our business, including: the June 2015 acquisition of Jianghai Environmental Protection Co. Ltd, an industrial water treatment company headquartered in Changzhou, China; the November 2015 acquisition of the U.S. operations of Charlotte, N.C. – based Swisher Hygiene Inc, a provider of hygiene and sanitizing solutions for the foodservice, hospitality, retail and healthcare markets; and the November 2015 acquisition of the assets and operations of Calgary – based Ultra Fab Industries Ltd, which manufactures customized solutions and specialized chemical injection systems for the oil and gas industry. See Part II, Item 8, Note 4 of this Form 10-K for additional information about these three acquisitions as well as additional actions taken by the Company.   Advisors’ Opinion:

  • [By Ethan Ryder]

    TRADEMARK VIOLATION WARNING: “Ecolab (ECL) Sets New 52-Week High at $173.40” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4218879/ecolab-ecl-sets-new-52-week-high-at-173-40.html.

  • [By Maxx Chatsko]

    Last year,Ecolab (NYSE:ECL) had to navigate headwinds including global currency fluctuations made worse by a strong U.S. dollar, rising delivery costs, and volatility in energy markets. The business attempted to offset cost increases by improving operating efficiency and increasing selling prices, but those efforts weren’t enough to stop fourth-quarter operating income from sliding 4% compared to 2017. Revenue increased 3% year over year.

  • [By Motley Fool Transcription]

    Ecolab Inc. (NYSE:ECL)Q4 2018 Earnings Conference CallFebruary 19, 2019, 1:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Undervalued Stocks To Own Right Now: CIM Commercial Trust Corporation(CMCT)

CIM Commercial Trust Corporation (CIM Commercial), incorporated on April 25, 2014, is engaged in acquiring, owning and operating Class A office investments in urban communities throughout the United States. These communities are located in areas that include traditional downtown areas and suburban main streets. The Company operates in the business segments, including the acquisition, redevelopment, ownership and management of office real estate, multifamily real estate and hotels. The Company’s real estate portfolio consists of approximately 30 assets, all of which are fee-simple properties except one leasehold property. It has approximately 20 office properties (including over two parking garages, one of which has street level retail space, and over two development sites, one of which is being used as a parking lot), totaling approximately 5.6 million rentable square feet, which are approximately 86.9% occupied; multifamily properties, composed of over 930 units, which are approximately 92.4% occupied, and hotels, which have a total of approximately 1,070 rooms. Its office, multifamily and hotel assets are located in over 10 of the United States markets. The Company is managed by affiliates of CIM Group, L.P. (CIM Group or CIM).

The Company seeks risk adjusted returns by utilizing the CIM platform. The Company invests primarily in substantially stabilized real estate and real estate related assets located in areas that CIM has targeted for opportunistic investment. CIM targets investments in diverse types of real estate assets, including office, retail, for rent and for sale multifamily residential, hotel, parking, and signage through CIM’s network and its opportunistic investment activities.

Advisors’ Opinion:

  • [By Logan Wallace]

    Crowd Machine (CURRENCY:CMCT) traded down 3.1% against the U.S. dollar during the 1-day period ending at 18:00 PM ET on February 2nd. One Crowd Machine token can currently be bought for approximately $0.0023 or 0.00000066 BTC on major cryptocurrency exchanges including Bancor Network, BitForex, Bittrex and HitBTC. During the last seven days, Crowd Machine has traded down 41.4% against the U.S. dollar. Crowd Machine has a total market capitalization of $1.09 million and approximately $553,701.00 worth of Crowd Machine was traded on exchanges in the last day.

  • [By Shane Hupp]

    CIM Commercial Trust (NASDAQ:CMCT) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

  • [By Joseph Griffin]

    Crowd Machine (CURRENCY:CMCT) traded 9.6% lower against the US dollar during the 24-hour period ending at 0:00 AM ET on May 14th. Over the last week, Crowd Machine has traded down 49% against the US dollar. One Crowd Machine token can now be bought for approximately $0.0436 or 0.00000499 BTC on exchanges including Coinhub, BitForex and HitBTC. Crowd Machine has a market capitalization of $0.00 and $233,116.00 worth of Crowd Machine was traded on exchanges in the last 24 hours.

  • [By Jack Delaney]

    CIM Commercial Trust Corp. (NYSE: CMCT) acquires, owns, and operates office properties in the United States.

    It has a portfolio of more than 100 buildings that is valued at a combined $25 billion, according to BizJournals.com.

Top 5 Undervalued Stocks To Own Right Now: Pagegroup PLC (PAGE)

PageGroup plc, formerly Michael Page International plc, is a United Kingdom-based recruitment consultancy. The Company’s segments include EMEA, United Kingdom, Asia Pacific and Americas. The Company is organized into three brands operating at different levels of the market: Michael Page, Page Personnel and Page Executive. Page Executive offers executive search services. Page Executive provides a range of search, selection and management solutions for organizations on a permanent and interim basis. Michael Page recruits on a permanent, temporary, contract, and interim basis from second/third job levels upward. Page Personnel offer specialist recruitment services to organizations requiring permanent employees or temporary or contract staff at technical and administrative support, professional clerical and junior management levels. The Company provides specialist services to organizations requiring talent at the professional clerical and support levels. Advisors’ Opinion:

  • [By Shane Hupp]

    Pagegroup (LON:PAGE) had its target price cut by equities researchers at Jefferies Financial Group from GBX 610 ($7.97) to GBX 590 ($7.71) in a note issued to investors on Tuesday, ThisIsMoney.Co.Uk reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 10.90% from the stock’s previous close.

  • [By Joseph Griffin]

    Pagegroup (LON:PAGE) had its target price reduced by Royal Bank of Canada from GBX 670 ($8.75) to GBX 620 ($8.10) in a note issued to investors on Monday. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s price target would indicate a potential upside of 30.86% from the stock’s current price.

Top 5 Undervalued Stocks To Own Right Now: Fiserv, Inc.(FISV)

Fiserv, Inc. is a leading global provider of financial services technology. We are publicly traded on the NASDAQ Global Select Market and part of the S&P 500 Index. We serve approximately 14,500 clients worldwide, including banks, thrifts, credit unions, investment management firms, leasing and finance companies, retailers, and merchants. We provide account processing systems; electronic payments processing products and services, such as electronic bill payment and presentment services, card-based transaction processing and network services, ACH transaction processing, account-to-account transfers, and person-to-person payments; internet and mobile banking systems; and related services including document and payment card production and distribution, check processing and imaging, source capture systems, and lending and risk management products and services.   Advisors’ Opinion:

  • [By Billy Duberstein]

    In particular, Palmer worries about Fiserv’s (NASDAQ:FISV)recent acquisition of First Data (NYSE:FDC). First Data makes the Clover point-of-sale system, a Square competitor. The combined companies say they intend to spend over $500 million over five years to “accelerate growth,” which likely means putting serious weight behind Clover.

  • [By Shane Hupp]

    Fiserv (NASDAQ:FISV) last released its quarterly earnings data on Thursday, February 7th. The business services provider reported $0.84 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.84. Fiserv had a return on equity of 47.56% and a net margin of 20.39%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the firm posted $0.71 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts expect that Fiserv Inc will post 3.46 EPS for the current fiscal year.

    ILLEGAL ACTIVITY NOTICE: “Checchi Capital Advisers LLC Has $581,000 Position in Fiserv Inc (FISV)” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at www.tickerreport.com/banking-finance/4163064/checchi-capital-advisers-llc-has-581000-position-in-fiserv-inc-fisv.html.

    Fiserv Profile

  • [By Max Byerly]

    Cerity Partners LLC reduced its stake in Fiserv Inc (NASDAQ:FISV) by 0.5% during the fourth quarter, HoldingsChannel reports. The firm owned 27,751 shares of the business services provider’s stock after selling 139 shares during the quarter. Cerity Partners LLC’s holdings in Fiserv were worth $2,039,000 as of its most recent SEC filing.

Top 5 Undervalued Stocks To Own Right Now: Jazz Pharmaceuticals Inc.(JAZZ)

Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products to meet unmet medical needs. The company markets Xyrem, a sodium oxybate oral solution for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR extended-release capsules for the treatment of obsessive compulsive disorder. Its product candidates under clinical development include JZP-6, a Phase III pivotal clinical trials completed product for the treatment of fibromyalgia; and JZP-8, an intranasal formulation of clonazepam, which has completed Phase II clinical trial for the treatment of acute repetitive seizures in epilepsy and solid oral dosage forms of sodium oxybate. The company sells its products through specialty sales force targeting sleep specialists, psychiatrists, neurologists, and pulmonologists. Jazz Pharmaceuticals, Inc. was founded in 2003 and is headq uartered in Palo Alto, California.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    COPYRIGHT VIOLATION NOTICE: “Matthew P. Young Sells 1,152 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at www.tickerreport.com/banking-finance/4204759/matthew-p-young-sells-1152-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

  • [By Keith Speights]

    The three best biotech bargains on the market right now based on PEG ratios are Celgene (NASDAQ:CELG), Exelixis (NASDAQ:EXEL), and Jazz Pharmaceuticals (NASDAQ:JAZZ). Here’s why these biotech stocks are priced attractively.

Best Warren Buffett Stocks To Watch Right Now

&l;p&g;The stock market was hammered by trade tariff threats again this week, a frequent occurrence during this administration. Based on last week&a;rsquo;s public comments, some Republican representatives are now becoming more worried. Without any concrete policy changes actually occurring, no one can be sure whether the threats are real, or just part of the negotiation strategy.

&l;img class=&q;dam-image getty size-large wp-image-978636016&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/978636016/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; (Photo by Drew Angerer/Getty Images)

The Dow Industrials managed to close higher on Friday, avoiding the longest daily losing streak since 1978. Then, the Dow closed lower for eight days in a row, and a losing day on Friday would have been nine days in a row.&a;nbsp; Again, this kind of streak has not happened &l;a href=&q;https://www.marketwatch.com/story/trade-concerns-could-give-the-dow-its-longest-losing-streak-since-the-70s-2018-06-21&q; target=&q;_blank&q;&g;since February 1978&l;/a&g;.

Best Warren Buffett Stocks To Watch Right Now: MV Oil Trust(MVO)

MV Oil Trust (the Trust), incorporated on August 3, 2006, is a statutory trust. The Trust acquires and holds a term net profits interest for the benefit of the Trust unitholders. MV Partners, LLC (MV Partners) is a limited liability company engaged in the exploration, development, production, gathering and aggregation and sale of oil and natural gas, primarily in the Mid-Continent region in the United States. The Trust has interest in underlying properties consisting of MV Partner’s net interests in all of its oil and natural gas properties located in the Mid-Continent region in the states of Kansas and Colorado. These oil and gas properties include approximately 1,000 producing oil and gas wells. The Trust is managed by Bank of New York Mellon Trust Company, N.A. as Trustee. Approximately 62% of the net acres included in the Trust’s underlying properties are located in the El Dorado Area, which is in southeastern Kansas, and in the Northwest Kansas Area.

El Dorado Area

The underlying properties located in the El Dorado Area are operated on behalf of MV Partners by Vess Oil and are located in the El Dorado, Augusta and Valley Center Fields. Vess Oil Corporation (Vess Oil) is involved in infill drilling, well re-entries, plugback and deepening recompletion operations, and various types of restimulation work and equipment optimization programs to reduce the natural decline in production from these fields. The El Dorado Field is located atop the Nemaha Ridge in Central Butler County, Kansas. Up to 15 horizons contain hydrocarbons, ranging from the Admire Sands, at a depth of 650 feet, to the Arbuckle Dolomite, at a depth of 2,500 feet. The primary producing intervals are the Admire, Lansing-Kansas City, Viola, Simpson and Arbuckle. The Augusta Field covers approximately 10 square miles of Butler County, Kansas. The Trust is primarily engaged in the production at the Arbuckle interval along with the Simpson and Lansing-Kansas City intervals. The Augusta Field is an extension of t! he El Dorado Field. The Valley Center Field covers approximately 60 square miles of Sedgwick County, Kansas. The Valley Center Field production operations are located at the Viola interval, which is located at an average depth of 2,500 feet.

Northwest Kansas Area

Each of Vess Oil and Murfin Drilling Company, Inc. (Murfin Drilling) operate leases on behalf of MV Partners at the underlying properties that are located in the Northwest Kansas Area. The primary fields in this area are the Bemis-Shutts, Trapp, Ray and Hansen Fields. Vess Oil and Murfin Drilling are engaged in polymer treatment program at these fields. The Bemis-Shutts Field is located on the Fairport Anticline within the Central Kansas Uplift. The field consists of 17,080 acres in northeastern Ellis and southeastern Rooks Counties, Kansas. The Trust is engaged in the production at the Arbuckle interval at a depth of 3,300 feet and the Lansing-Kansas City interval at a depth of 2,800 feet. The Trapp Field consists of 35,900 acres in Russell and Barton Counties, Kansas. Production is primarily from the Lansing-Kansas City and Shawnee limestones and the Arbuckle dolomite. The Hansen Field is located along the crest of the Stuttgart-Huffstutor Anticline. Production from this field is primarily come from the Lansing-Kansas City limestone. The Ray Field is located on the eastern flank of the Central Kansas Uplift. Production is primarily from the Arbuckle dolomite and the Gorham sands with additional production from the Lansing-Kansas City interval along the eastern flank of the field. The Hansen and Ray Fields consist of over 7,000 acres in Philips and Norton Counties, Kansas. Murfin Drilling operates the leases held by MV Partners in the Trapp, Hansen and Ray Fields.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Jones Energy (NYSE: MVO) and MV Oil Trust (NYSE:MVO) are both small-cap oils/energy companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

  • [By Max Byerly]

    MV Oil Trust (NYSE: MVO) and Petroleo Brasileiro SA Petrobras (NYSE:PBR.A) are both oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Best Warren Buffett Stocks To Watch Right Now: PowerShares Global Water ETF (PIO)

PowerShares Global Water Portfolio (the Fund) seeks investment results that generally correspond to the price and yield performance of the NASDAQ OMX Global Water Index (the Index). The Fund will invest at least 90% of its total assets in the equity securities that comprise the Index, American depository receipts (ADR) and Global depository receipts (GDR) that are based on the securities in the Index. The Index consisted of companies listed on exchanges in Australia, Bermuda, Brazil, Canada, Chile, China, Egypt, France, Hong Kong, India, Indonesia, Israel, Luxembourg, Malaysia, Mexico, Poland, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan and the United States. The Fund’s investment adviser is Invesco PowerShares Capital Management LLC.
Advisors’ Opinion:

  • [By ]

    No wonder water-centric funds like the Invesco Global Water ETF (NYSE: PIO) are at 52-week highs and climbing.

    While these are all worthy candidates for further research if you’re interested, unfortunately, these stocks aren’t exactly synonymous with dividends. Many have little to no yield. But one industry leader has been raising its distributions every year since 2008 — with $8 billion budgeted to spur future growth and ensure that streak remains intact.

  • [By Shane Hupp]

    Raymond James Financial Services Advisors Inc. trimmed its holdings in INVESCO EXCHANG/GLB WTR ETF (NASDAQ:PIO) by 34.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,967 shares of the company’s stock after selling 7,204 shares during the quarter. Raymond James Financial Services Advisors Inc. owned about 0.20% of INVESCO EXCHANG/GLB WTR ETF worth $349,000 at the end of the most recent quarter.

Best Warren Buffett Stocks To Watch Right Now: Fiat Chrysler Automobiles N.V.(FCAU)

Fiat Chrysler Automobiles N.V., incorporated on April 1, 2014, is an automotive company. The Company is engaged in designing, engineering, manufacturing, distributing and selling vehicles, and components. The Company’s activities are carried out through six reportable segments: four regional mass-market vehicle segments (NAFTA, LATAM, APAC and EMEA), Maserati, and a global Components segment. The Company has operations in approximately 40 countries and sells its vehicles for the mass market under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia and Ram brands, and the SRT performance vehicle designation. In addition, the Company designs, engineers, manufactures, distributes and sells luxury vehicles under the Maserati brand. The Company also operates in the components and production systems sectors under the Magneti Marelli, Teksid and Comau brands. The Company manufactures and sells passenger cars, light trucks and light commercial vehicles.

The Company’s NAFTA segment includes its operations to support distribution and sales of mass-market vehicles in the United States, Canada, Mexico and Caribbean islands, through the Chrysler, Dodge, Fiat, Jeep and Ram brands. LATAM segment includes its operations to support the distribution and sale of mass-market vehicles in South and Central America primarily under the Fiat, Jeep, Chrysler, Dodge and Ram brands, with the focus of its business in the LATAM segment in Brazil and Argentina. APAC segment includes its operations to support the distribution and sale of mass-market vehicles in the Asia Pacific region (in China, Japan, Australia, South Korea and India) carried out in the region through both subsidiaries and joint ventures, primarily under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat and Jeep brands. EMEA segment includes operations to support the distribution and sale of mass-market vehicles in Europe (which includes the over 28 members of the European Union and the members of the European Free Trade Associat! ion), the Middle East and Africa primarily under the Abarth, Alfa Romeo, Chrysler, Fiat, Fiat Professional, Jeep and Lancia brand names. Maserati segment includes design, engineering, development, manufacturing, around the world distribution and sale of luxury vehicles under the Maserati brand. The Components segment includes production and sale of lighting components, body control units, suspensions, shock absorbers, electronic systems, and exhaust systems and activities in powertrain (engine and transmissions) components, engine control units, plastic molding components and in the after-market carried out under the Magneti Marelli brand name; cast iron components for engines, gearboxes, transmissions and suspension systems, and aluminum cylinder heads under the Teksid brand name, and design and production of industrial automation systems and related products for the automotive industry under the Comau brand name. The Company’s other activities primarily consists of companies that provide services, including accounting, payroll, tax, insurance, purchasing, information technology, facility management and security for the Company, as well as CNH Industrial N.V. (CNHI), which manages central treasury activities and operates in media and publishing.

The Company designs, engineers, develops, manufactures, distributes and sells vehicles and service parts under approximately 10 mass-market brands and designations. The Company has over 50 parts distribution centers throughout the world to support its customer care efforts. Its passenger car product portfolio includes vehicles, such as the Fiat 500, Alfa Romeo Giulietta, Dodge Charger and Lancia Ypsilon. Its light commercial vehicles include vans, such as the Fiat Professional Doblo, Fiat Professional Ducato and Ram ProMaster, and light and heavy-duty pickup trucks, such as the Ram 1500 and 2500/3500. The Company also sells sport utility vehicles (SUVs) and compact utility vehicles (CUVs) in various vehicle segments, such as the Jeep Grand Cherokee! , includi! ng Jeep Renegade. The Company’s Mopar brand accessories allow its customers to customize their vehicles by including after-market sales of products from side steps and lift-kits, to graphics packages, such as racing stripes and custom leather interiors. Through the Mopar brand, it offers vehicle service contracts to its retail customers around the world under the Mopar Vehicle Protection brand.

Advisors’ Opinion:

  • [By Shane Hupp]

    Workhorse Group (NASDAQ:WKHS) and Fiat Chrysler Automobiles (NYSE:FCAU) are both auto/tires/trucks companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

  • [By Shane Hupp]

    ILLEGAL ACTIVITY NOTICE: “Camelot Portfolios LLC Boosts Holdings in Fiat Chrysler Automobiles NV (FCAU)” was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at www.tickerreport.com/banking-finance/4200823/camelot-portfolios-llc-boosts-holdings-in-fiat-chrysler-automobiles-nv-fcau.html.

  • [By John Rosevear]

    Fiat Chrysler Automobiles (NYSE:FCAU) has taken the wraps off a new concept for its upscale Alfa Romeo brand. Unsurprisingly, given global sales trends, it’s a compact SUV — but in a bit of a surprise for Alfa, it’s also a plug-in hybrid.

  • [By Chris Lange]

    Fiat Chrysler Automobiles N.V. (NYSE: FCAU) is planning to expand its footprint in Michigan, specifically Detroit. The automaker confirmed plans to invest a total of $4.5 billion in five of its existing Michigan plants

Best Warren Buffett Stocks To Watch Right Now: Natural Health Trends Corp.(NHTC)

Natural Health Trends Corp., a direct-selling and e-commerce company, provides wellness, beauty, and lifestyle products for consumers or business builders under the NHT Global brand name. The company manufactures and supplies its products through third parties. Its wellness products include liquid, encapsulated, tableted and powder dietary and nutritional supplements, herbal supplements, vitamins, and minerals. The companys beauty products comprise anti-aging and hydrating cleansers, creams, lotions, serums, and toners; and lifestyle products include weight management, intimacy support, and energy enhancing supplements. It operates in North America, Hong Kong, Taiwan, South Korea, Japan, Italy, and Slovenia, as well as in Russia, Kazakhstan, and Ukraine. The company sells its products through its network marketing operations, as well as sells directly to consumers through an e-commerce platform. Natural Health Trends Corp. was founded in 1988 and is headquartered in Rolling Hills Estates, California.

Advisors’ Opinion:

  • [By Shane Hupp]

    Natural Health Trends (NASDAQ:NHTC) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

  • [By Max Byerly]

    Central Garden & Pet (NASDAQ: CENT) and Natural Health Trends (NASDAQ:NHTC) are both consumer discretionary companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Natural Health Trends Corp (NASDAQ: NHTC) fell 7.8 percent to $19.80 in pre-market trading after rising 1.46 percent on Friday.
    Endocyte, Inc. (NASDAQ: ECYT) shares fell 6.6 percent to $11.41 in pre-market trading after climbing 4.18 percent on Friday.
    Quorum Health Corporation (NYSE: QHC) shares fell 6.2 percent to $5.15 in pre-market trading after tumbling 11.45 percent on Friday.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) fell 6.1 percent to $7.31 in pre-market trading after declining 3.35 percent on Friday.
    Boston Scientific Corporation (NYSE: BSX) fell 5.6 percent to $28.30 in pre-market trading.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) fell 5.3 percent to $6.06 in pre-market trading after gaining 2.73 percent on Friday.
    Xerox Corporation (NYSE: XRX) shares fell 5.2 percent to $28.60 in pre-market trading. Xerox terminated its transaction agreement with Fujifilm and entered into a new agreement with Carl Icahn and Darwin Deason. JP Morgan downgraded Xerox from Overweight to Neutral.
    Cellcom Israel Ltd. (NYSE: CEL) fell 5.2 percent to $7.02 in pre-market trading. Cellcom is expected to release Q1 results on May 30, 2018.
    Perrigo Company plc (NYSE: PRGO) fell 4.5 percent to $74 in pre-market trading.
    Nabriva Therapeutics plc (NASDAQ: NBRV) shares fell 4 percent to $4.66 in pre-market trading

Best Warren Buffett Stocks To Watch Right Now: Qualstar Corporation(QBAK)

Qualstar Corporation and its Subsidiary (“Qualstar”, the “Company”, “we”, “us” or “our”) is a leading provider of data storage systems marketed under the Qualstar brand and of high efficiency and high density power solutions marketed under the N2Power brand. Qualstar was incorporated in California in 1984. Qualstar is organized into two strategic business units, power solutions and data storage systems. Power solutions products include ultra-small high efficiency switching power supplies that provide unique power solutions to original equipment manufacturers (“OEMs”) for a wide range of markets, including communications networking, industrial, gaming, test equipment, LED/lighting, medical as well as other market applications.   Advisors’ Opinion:

  • [By Max Byerly]

    Qualstar (NASDAQ:QBAK) issued its quarterly earnings data on Wednesday. The electronics maker reported $0.23 earnings per share for the quarter, Bloomberg Earnings reports. Qualstar had a net margin of 10.52% and a return on equity of 20.76%. The business had revenue of $3.23 million during the quarter.

  • [By Ethan Ryder]

    Media headlines about Qualstar (NASDAQ:QBAK) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qualstar earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news headlines about the electronics maker an impact score of 45.8526636437463 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Best Warren Buffett Stocks To Watch Right Now: CommunityOne Bancorp(COB)

Cobalt Blue Holdings Ltd is focused on achieving commercial production of cobalt and commercializing technical advances in the use of cobalt. The Company is focused on financing and undertaking an exploration and development program with potential to support a mine at Thackaringa Cobalt Project. The Thackaringa Cobalt Project comprises mineralized system, strategically located approximately 25 kilometers south-east of Broken Hill. The Company is a subsidiary of Broken Hill Prospecting Limited. Advisors’ Opinion:

  • [By Joseph Griffin]

    Cobinhood (CURRENCY:COB) traded up 12.3% against the U.S. dollar during the 24-hour period ending at 12:00 PM Eastern on October 13th. During the last week, Cobinhood has traded 0.4% higher against the U.S. dollar. Cobinhood has a total market cap of $10.06 million and $24,249.00 worth of Cobinhood was traded on exchanges in the last day. One Cobinhood token can currently be bought for approximately $0.0268 or 0.00000430 BTC on cryptocurrency exchanges including Cobinhood and Mercatox.

  • [By Stephan Byrd]

    Cobinhood (CURRENCY:COB) traded up 1.6% against the dollar during the 1 day period ending at 17:00 PM ET on September 3rd. During the last seven days, Cobinhood has traded up 13.8% against the dollar. One Cobinhood token can now be purchased for approximately $0.0354 or 0.00000486 BTC on major cryptocurrency exchanges including Mercatox and Cobinhood. Cobinhood has a total market capitalization of $13.14 million and $26,663.00 worth of Cobinhood was traded on exchanges in the last day.

Hot Biotech Stocks To Own Right Now

Credit reporting agency Equifax
EFX, +0.91%
said Tuesday its chairman and chief executive Richard Smith will retire, after a security breach at the company that potentially exposed about 143 million U.S. adults to identity theft.

Hot Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler — five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies that are innovating treatments and drugs that are making the world healthier. Learn more about Amgen (NASDAQ:AMGN), bluebird bio (NASDAQ:BLUE), Editas Medicine (NASDAQ:EDIT), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) and why you should add these exciting and inspiring stocks to your watch list.

  • [By ]

    Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.

  • [By Brian Feroldi]

    Amgen (NASDAQ:AMGN) andBiogen(NASDAQ:BIIB)have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.

  • [By Cory Renauer]

    A government proposal in the works could lead to important changes that benefit patients and drugmakers, but the industry isn’t going to wait that long.Eli Lilly (NYSE:LLY) recently fired a big arrow at the bulging rebate bubble following signs of success fromAmgen(NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Here’s what you need to know about their effort to change the drug pricing landscape.

Hot Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Just last Thursday, March 21, Biogen (Nasdaq: BIIB) and its partner, Japanese biopharmaceutical company Eisai (OTC: ESALY), said that their experimental Alzheimer’s therapy, which at that time was at the second stage of clinical trials, was a bust. BIIB dropped 29.2% on the day, and ESALY by 35% on the same day.

  • [By Chris Hill]

    In this episode ofMotley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS)finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health(NYSE:CVS) diversifies into CBD lotion. Levi Strauss(NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE)sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s(NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc.(NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

  • [By Money Morning News Team]

    Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

Hot Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator